A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Irinotecan
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 12 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 Planned number of patients changed from 78 to 65.